The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail

Wed, 20th Mar 2024 18:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Transense Technologies PLC - Bicester, Oxfordshire-based developer of specialist sensor systems for vehicles - Appoints Ryan Maughan as managing director with immediate effect. Maughan joined Transense on a part-time basis as business development director of SAWsense on December 1 2021.

----------

ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Appoints Cork Gully LLP as administrators. Says talks with creditors to establish the solvency of the business, have taken place, with a particular focus on finding solutions that would allow the group to continue trading on a lower cost model. However, to date, these discussions have not progressed sufficiently to establish the precise solvency status of the business. Therefore, due to this increased financial uncertainty the decision has been taken to appoint administrators. Stresses discussions with potential investors, partners and creditors will remain open throughout the administration process.

----------

Downing Strategic Micro-Cap IT PLC - London-based investment trust - Updates on return of capital to shareholders. Says that the level of cash within the company's portfolio against the net asset value as at March 6 has increased to over 40%. Therefore, anticipates that it will be able to undertake an issue and redemption of B shares on or around April 4. This will enable a return capital of around 26.0 pence per share to shareholders. Says this is significantly improved on the previous anticipated return of around GBP10 million, or 21.5p per share.

----------

BAE Systems PLC - London-based defence, aerospace and security company - Announces private placement of notes to institutional buyers. Notes to be issued consist of USD800 million in aggregate principal amount of 5.000% notes due 2027, USD1.25 billion in aggregate principal amount of 5.125% notes due 2029, USD500 million in aggregate principal amount of 5.250% notes due 2031, USD1.50 billion in aggregate principal amount of 5.300% notes due 2034 and USD750 million in aggregate principal amount of 5.500% notes due 2054. Net proceeds will be used to refinance USD4.0 billion in aggregate principal amount outstanding under the bridge loan facility agreement incurred to fund part of the acquisition price of Ball Aerospace, and for general corporate purposes. Notes the offering is expected to close on or about March 26.

----------

Cloudbreak Discovery PLC - Vancouver, Canada-based natural resource project generator - Says Andrew Male and Paul Gurney have joined the Board of G2 Energy Ltd. Male is interim chief executive of Cloudbreak. Gurney is a non-executive director. Male states: "Paul and I look forward to working with G2 and their team in order to develop and enhance the production assets that G2 hold. Our primary focus will be to assist G2 in generating more revenue and looking at additional acquisitions that are accretive to the Cloudbreak investment and G2's underlying business operations."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
15 Apr 2014 12:23

ReNeuron leases building for relocation of business

AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales. The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next ye

Read more
15 Apr 2014 10:01

ReNeuron Leases New Research & Development Facility With Welsh Government

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC said Tuesday that it had signed an agreement with the Welsh Government to lease a new research and development facility at the Pencoed Technology Park near Cardiff, South Wales. ReNeuron expects to begin to relocate its o

Read more
15 Apr 2014 07:50

UK MORNING BRIEFING: Aggreko Leads After Mixed Results

LONDON (Alliance News) - Aggreko is leading the FTSE 100 in early trading Tuesday after the temporary power company said it has seen mixed results in its first quarter, with strong underlying revenue growth in two of its three regions being impacted by adverse currency movements as previously exp

Read more
27 Mar 2014 13:48

UK MIDDAY BRIEFING: Regulators Confirm UK Energy Market Review

LONDON (Alliance News) - UK regulators have now confirmed they will investigate whether the country's major energy companies are preventing effective competition in the market, a decision that prompted British Gas parent Centrica to warn that the review could delay crucial investments in new i

Read more
27 Mar 2014 13:01

UK WINNERS & LOSERS: Babcock, Tullow Oil Lead Blue-Chip Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.

-------

FTSE 100 - WINNERS

Old Mutual, up 0.5%. The group has agreed to sell Skandia Germany and S

Read more
27 Mar 2014 11:13

ReNeuron Gets Approvals To Begin Two New Trials Using Stem Cell Product

LONDON (Alliance News) - ReNeuron Group PLC said Thursday that it has received final regulatory and ethical approvals to begin two new clinical trials using its CTXcyro stem cell product. The company will begin a Phase II clinical trial of its ReN001 investigational therapy in stroke disabi

Read more
14 Mar 2014 13:04

ReNeuron Eyes New UK Government Scheme Encouraging Novel Therapies

LONDON (Alliance News) - ReNeuron Group PLC Friday said it will look at whether the UK government's plan to launch a scheme to encourage the take up of novel therapies could be applied to its own therapeutic candidates. The scheme, called the Early Access to Medicines Scheme, is looking to

Read more
11 Mar 2014 12:48

US foundation funds ReNeuron stem cell therapy

A US-based charity has agreed to provide funding and access to clinical expertise for ReNeuron's retinal stem cell therapy candidate for a degenerative eye disease. Shares in ReNeuron rose 8.8% to 3.54p on the news. The Foundation for Fighting Blindess has agreed to provide further funding toward

Read more
11 Mar 2014 11:27

ReNeuron Retinal Stem Cell System Wins FFB Support

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday its retinal stem cell therapy candidate is to receive support from a retinal research funding foundation. ReNeuron said its ReN003 retinal stem cell therapy candidate for the treatment of retinis pigmentosa is set to receive support

Read more
21 Jan 2014 10:04

ReNeuron Sees Positive Data For Stem Cells In Retinal Degeneration Test

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday that a paper detailing the efficiency of its human retinal stem cells in a test model of retinal degeneration had been published in the Journal of Biological Chemistry. The test showed that ReNeuron's cells protected visual function w

Read more
21 Jan 2014 08:19

UK MORNING BRIEFING: Shares Higher; Unilever, SABMiller As Expected

LONDON (Alliance News) - UK shares have opened higher Tuesday, as Unilever and SABMiller have released results and trading statements in line with expectations.

Peel Hunt has issued ratings on the property sector, cutting Great Portland Est

Read more
13 Sep 2013 09:02

ReNeuron Moving All Therapeutic Programmes To Phase II Trials In Next 3 Years

Read more
22 Jul 2013 10:50

ReNeuron announces capital increase, funds to enter capital structure

Lifesciences group ReNeuron has announced that it has successfully raised 33m pounds in fresh funding to finance its research into stem-cell development, although it had to offer a small discount for the new equity. Significantly, three new investment funds are to enter its shareholder register with

Read more
28 May 2013 10:39

ReNeuron jumps on stem cell study results

Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The group said that the primary aim of the study was to test the safety and toler

Read more
26 Mar 2013 09:45

ReNeuron Group to begin stem cell treatment of critical limb ischaemia

ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia. Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to am

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account